Exicure, Inc. (XCUR) - 10-Q Summary for Period Ended June 30, 2026
Business Context and Reporting Period
This is an unaudited Quarterly Report (Form 10-Q) for Exicure, Inc., a smaller reporting company and non-accelerated filer, for the period ended June 30, 2026. The company, historically an early-stage biotechnology firm, has undergone significant changes in ownership, board composition, and management. Current operations focus on supporting the clinical development of its subsidiary, GPCR Therapeutics USA Inc. (GPCR USA), and evaluating strategic alternatives to maximize stockholder value. The company has no current revenue-generating operations.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,949,000) | $389,000 (Income) |
| Operating Expenses | $2,694,000 | $(414,000) (Net Gain) |
| Cash and Cash Equivalents (End of Period) | $1,717,000 | $7,858,000 |
| Net Cash Used in Operating Activities | $(2,029,000) | $(3,880,000) |
| Total Liabilities | $10,420,000 | $10,115,000 |
| Stockholders' Equity | $977,000 | $3,926,000 |
Note: The 2025 operating results included a one-time gain of $5.974 million from an early lease termination, which significantly impacted the prior period's net income.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses for the six months ended June 30, 2026, were $2.69 million, compared to a net operating gain of $0.41 million in the prior year. Excluding the non-recurring lease termination gain in 2025, operating losses improved due to significant reductions in headcount (from 8 to 1 full-time employee in G&A) and deferred clinical development costs.
- Research & Development (R&D): R&D expenses decreased by 72% to $0.49 million from $1.74 million year-over-year, primarily due to the deferral of clinical program expenses pending restructuring.
- Liquidity: Cash and cash equivalents declined by approximately $2.0 million to $1.7 million, reflecting continued negative cash flows from operations.
- Contingent Consideration: The fair value of contingent consideration liability increased by $240,000 during the period due to revised estimates regarding the probability and timing of milestone achievements.
Outlook, Risks, and Management Commentary
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months. Current cash reserves are insufficient to fund planned operations, and additional financing is required. Failure to secure funding could lead to bankruptcy or cessation of operations.
- Strategic Alternatives: The company is actively exploring strategic alternatives, including acquisitions, financings, and business combinations, but no assurance is given that a transaction will be consummated.
- Nasdaq Compliance: The company received a deficiency notice from Nasdaq regarding minimum stockholders' equity requirements (reported equity of $2.098 million vs. $2.5 million requirement). A Plan of Compliance was submitted on July 30, 2026, and the company is awaiting approval for a potential 180-day extension.
- Legal Proceedings:
- Lease Dispute: The company vacated its Redwood City facility in April 2026 after receiving a notice to pay approximately $0.7 million in unpaid rent. The landlord has filed a complaint for unlawful detainer.
- Settlements: A securities class action was settled for $5.625 million (covered by insurance, with a $1 million self-insured retainer paid in August 2025). Derivative lawsuits were settled in June 2026. A former employee lawsuit was settled for $425,000 in July 2026.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding the review of non-routine activities and the design of accounting/IT processes.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $1.7 million cash balance against the stated need for additional financing to survive the next 12 months.
- Nasdaq Status: Monitor the outcome of the Plan of Compliance submitted to Nasdaq to avoid potential delisting.
- Legal Exposure: Assess the potential financial impact of the Redwood City lease dispute ($0.7 million claim) and whether the company has accrued sufficient reserves.
- Strategic Progress: Track the status of the exploration of strategic alternatives and any potential equity offerings to fund operations.
- Contingent Liability: Review the assumptions used to value the $5.8 million contingent consideration liability, as changes in probability estimates can materially impact net loss.